Grant: Emerging Team Grant: Regenerative Medicine and Nanomedicine - LOI
Université Laval
$0.00
Treatment of muscular dystrophies with autologous genetically corrected iPS.
EF 2009-10
Résumé
The aim of this project is to develop stem cell therapies for various muscular dystrophies. The basic idea id to take a skin cell of a patient and change it into a pluripotent stem cell, called an iPSC. This iPSC will the be genetically corrected with a self replicating adenovirus, by integrating a corrective gene at a specific site in the cell genome or correcting the defective gene itself with a new molecular tool called Zinc Finger Nuclease. The genetically corrected stem cells will then be induced to differentiate into muscle precursor cells, which will be transplanted back in the patient muscles. As these would still be his own cells no immunosuppression will be required.
Programme
Emerging Team Grant: Regenerative Medicine and Nanomedicine - LOI
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
196521
Name
Tremblay Jacques P
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Emerging Team Grant: Regenerative Medicine and Nanomedicine
Projecttitle
Treatment of muscular dystrophies with autologous genetically corrected iPS.
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$0
Cihrequipment2
$0
Programname2
Emerging Team Grant: Regenerative Medicine and Nanomedicine - LOI
Keyworddelim
Cell Therapy; Dystrophies; Gene Therapy; Ips; Zinc Finger Nuclease
Abstract
The aim of this project is to develop stem cell therapies for various muscular dystrophies. The basic idea id to take a skin cell of a patient and change it into a pluripotent stem cell, called an iPSC. This iPSC will the be genetically corrected with a self replicating adenovirus, by integrating a corrective gene at a specific site in the cell genome or correcting the defective gene itself with a new molecular tool called Zinc Finger Nuclease. The genetically corrected stem cells will then be induced to differentiate into muscle precursor cells, which will be transplanted back in the patient muscles. As these would still be his own cells no immunosuppression will be required.
Competitiondate
200911
Approvedterm2
0 yr 0 mth
Pinamesdelim
Tremblay, Jacques P; Ellis, James R; Joung, Jae K
Approvedterm
0 an 0 mois
